Mechanisms of antipsoriatic effects of phosphodiesterase 4 inhibitors
- Author:
- No author available
- Journal Title:
- INTERNATIONAL JOURNAL OF DERMATOLOGY AND VENEREOLOGY
- Issue:
- 3
- DOI:
- 10.3760/cma.j.issn.1673-4173.2011.03.006
- Key Word:
- 银屑病;细胞因子类;磷酸二酯酶4;Psoriasis;Cytokines;Phosphodiesterase 4
Abstract： The phosphodiesterase (PDE) 4 is a predominant cyclic adenosine monophosphate (cAMP)degrading enzyme which can mediate inflammatory reactions via several routes. With broad anti-inflammatory activities, PDE4 inhibitors perform an antipsoriatic effect via a multifaceted and multitarget mechanism. Concretely, they can downregulate the production of pre-inflammatory cytokines including tumor necrosis factor (TNF)-α, interferon (IFN)-γ, interleukin (IL)-12 and IL-23 by modulating gene expression, inhibit the activation of dendrite cells and T cells and reduce the synthesis of inflammatory mediators. In addition, they have an anti-angiogenic potential. The efficacy and safety of PDE4 inhibitors have been confirmed in clinical trails. Thus, selective PDE4 inhibitors have excellent potential as new options for the treatment of psoriasis.
- [1]Nazarian R,Weinberg JM.AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis.[J].2009,10(11).
- [2]Kipnis C,Gottlieb AB,Krueger JG,etc.An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast.[J].2008,24(5).
- [3]Blauvelt A.T-helper 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasis.[J].2008,128(5).
- [4]Nestle FO,Kaplan DH,Barker J.Psoriasis.[J].2009,361(5).
- [5]Keravis T,Lugnier C.Cyclic nucleotide phosphodiesterases (PDE) and peptide motifs.[J].2010,16(9).
- [6]de-Fougerolles A,Laggner U,Kotelianski V,etc.Alpha1beta1 integrin is crucial for accumulation of epidermal T cells and the development of psoriasis.[J].2007,13(7).
- [7]Schafer PH,Parton A,Gandhi A.Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.[J].2010,159(4).
- [8]Baumer W,Hoppmann J,Rundfeldt C,etc.Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis.[J].2007,6(1).
- [9]Takashima Y,Takada C,Nosaka Y,etc.Effect of orally administered KF66490, a phosphodiesterase 4 inhibitor, on dermatitis in mouse models.[J].2009,9(1).
- [10]Asadullah K,Sterry W,Sabat R,etc.Interleukin-10: an important immunoregulatory cytokine with major impact on psoriasis.[J].2004,3(2).
- [11]Cardinale I,Khatcherian A,Bluth MJ,etc.Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses.[J].2007,204(13).
- [12]Harada D,Takashima Y,Tsukumo Y,etc.Effect of orally administered rolipram, a phosphodiesterase 4 inhibitor, on a mouse model of the dermatitis caused by 2,4,6-trinitro-1-chlorobenzene (TNCB)-repeated application.[J].2006,532(1).
- [13]Higgs G.Is PDE4 too difficult a drug target?[J].2010,11(5).
- [14]Ray A,Rajagopal D,Dastidar SG.Therapeutic benefit of PDE4 inhibitors in inflammatory diseases.[J].2007,8(5).
- [15]Georg, Schett,Victor S, Sloan,Randall M, Stevens,etc.Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases.[J].2010,2(5).